格雷夫兹病市场：依治疗方法、给药途径、分销管道和地区分类

预计2024年全球格雷夫兹病市场规模为4.101亿美元，预计2031年将达5.702亿美元，2024年至2031年复合年增长率为4.8%。

图 1. 2024 年格雷夫兹病市场占有率(%)，依地区划分

格雷夫兹病，也称为毒性瀰漫性甲状腺肿，是一种导致甲状腺激素分泌过多的自体免疫疾病。它是甲状腺亢进最常见的原因。当免疫系统产生刺激甲状腺生长并分泌过多甲状腺激素的抗体时，就会发生格雷夫兹病。过量的甲状腺激素会加速身体的许多功能。格雷夫兹病的常见症状包括震颤、焦虑、体重减轻、心悸和对热敏感。格雷夫兹病影响约 0.5% 的总人口，并且在女性中更为常见。这种疾病被认为具有遗传因素，并且经常在家族中遗传。儘管格雷夫兹病无法治愈，但可以透过抗甲状腺药物、放射性碘疗法以及切除部分或全部甲状腺的手术来有效治疗。

市场动态：

全球格雷夫兹病市场的成长是由人口老化加剧和甲状腺疾病盛行率上升等因素所推动的。据美国甲状腺协会称，格雷夫斯病每年影响约 0.5% 的美国人口。医疗保健支出的增加、新治疗方案的出现以及对疾病诊断和管理的认识不断提高也将推动市场成长。然而，与抗甲状腺药物相关的副作用，如体重增加、脱髮和肝损伤，可能会阻碍市场成长。此外，与手术和放射性碘治疗相关的高成本也可能阻碍市场成长。新药物分子和联合治疗的持续药物创新和临床试验可能会在预测期内为市场成长提供利润丰厚的机会。

本研究的主要特点

• 本报告对全球格雷夫兹病市场进行了详细分析，并提出了以2023年为基准年的预测期（2024-2031年）的市场规模和年复合成长率（CAGR%）。
• 它阐明了不同细分市场的潜在商机，并解释了该市场中有吸引力的投资提案的矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
• 根据公司亮点、产品系列、主要亮点、绩效和策略等参数，了解全球格雷夫兹病市场的主要企业概况。
• 该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
• 全球格雷夫兹病市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
• 透过用于全球格雷夫兹病市场分析的各种策略矩阵，将促进相关人员的决策。

目录

第一章 研究目的与前提

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行概述
• 一致的机会地图 (COM)

第三章 市场动态、法规与趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 机会
• 影响分析
• 市场趋势
• 监管场景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章全球格雷夫兹病市场－冠状病毒（COVID-19）大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第五章全球格雷夫兹病市场，依治疗方法，2019-2031 年，（百万美元）

• 介绍
• 抗甲状腺药物
• β阻断剂
• 碘疗法
• 放射性碘治疗
• 其他的

第六章 全球格雷夫兹病市场，依给药途径，2019-2031 年（百万美元）

• 介绍
• 口服
• 胃肠外的
• 其他的

第 7 章 全球格雷夫兹病市场，依通路划分，2019-2031 年（百万美元）

• 介绍
• 医院药房
• 零售药房
• 网路药房

第八章全球格雷夫兹病市场，按地区，2019-2031 年（百万美元）

• 介绍
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东

第9章 竞争格局

• 公司简介
  • AbbVie Inc.
  • Pfizer Inc.
  • RLC LABS, Inc.
  • Merck KGaA
  • Eisai Co., Ltd.
  • Novartis AG
  • Mylan NV
  • Aspen Pharmacare Holdings Limited
  • Sanofi
  • GlaxoSmithKline plc
  • AstraZeneca
  • Horizon Therapeutics plc
  • Alara Pharmaceutical Corporation
  • Antares Pharma, Inc.
  • Apitope Technology（Bristol）Ltd.
  • IONIS Pharmaceuticals, Inc.
  • Immunovant, Inc.
  • HanAll Biopharma Co., Ltd.
  • Cara Therapeutics

第10章分析师建议

• 升起和降落
• 综合机会图

第十一章 参考文献与调查方法

• 参考
• 调查方法

Global graves' disease (overactive thyroid) market is estimated to be valued at USD 410.1 Mn in 2024 and is expected to reach USD 570.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.

Figure 1. Graves' Disease (Overactive Thyroid) Market Share (%), By Region, 2024

Graves' disease, also known as toxic diffuse goiter, is an autoimmune disease that results in overproduction of thyroid hormones (hyperthyroidism). It is the most common cause of hyperthyroidism. Graves' disease develops when the immune system makes antibodies that stimulate the thyroid gland to grow and produce excess thyroid hormones. Excess thyroid hormones causes speeding up of many of the body's functions. Common symptoms of Graves' disease include tremors, anxiety, weight loss, heart palpitations, and heat intolerance. Graves' disease affects about 0.5% of the general population, although the disease is more common in women. The disease is believed to have a genetic component, and often runs in families. Although it is not curable, Graves' disease can be effectively treated by antithyroid medications, radioactive iodine therapy, or surgery to remove part or all of the thyroid gland.

Market Dynamics:

Global graves' disease (overactive thyroid) market growth is driven by factors like growing aging population and increasing prevalence of thyroid disorders. According to American Thyroid Association, Graves' disease affects about 0.5% of the population in the U.S. every year. Increasing healthcare expenditure, availability of newer treatment options, and rising awareness about disease diagnosis and management can also drive the market growth. However, side effects associated with antithyroid medications such as weight gain, hair loss and liver damage can hinder the market growth. High costs involved in surgeries and radioactive iodine therapy can also hamper the market growth. Ongoing drug innovations and clinical trials on newer drug molecules and combination therapies can offer lucrative opportunities for market growth over the forecast period.

Key Features of the Study:

• This report provides in-depth analysis of the global graves' disease (overactive thyroid) market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global graves' disease (overactive thyroid) market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie Inc., Pfizer Inc., RLC LABS, Inc., Merck KGaA, Eisai Co., Ltd., Novartis AG, Mylan N.V., Aspen Pharmacare Holdings Limited, Sanofi, GlaxoSmithKline plc, AstraZeneca, Horizon Therapeutics plc, Alara Pharmaceutical Corporation, Antares Pharma, Inc., Apitope Technology (Bristol) Ltd., IONIS Pharmaceuticals, Inc., Immunovant, Inc., HanAll Biopharma Co., Ltd., Cara Therapeutics
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global graves' disease (overactive thyroid) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global graves' disease (overactive thyroid) market

Detailed Segmentation-

• By Treatment
  • Anti-thyroid Drugs
  • Beta Blockers
  • Iodine Therapy
  • Radioactive Iodine Therapy
  • Others
• By Route of Administration
  • Oral
  • Parenteral
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AbbVie Inc.
  • Pfizer Inc.
  • RLC LABS, Inc.
  • Merck KGaA
  • Eisai Co., Ltd.
  • Novartis AG
  • Mylan N.V.
  • Aspen Pharmacare Holdings Limited
  • Sanofi
  • GlaxoSmithKline plc
  • AstraZeneca
  • Horizon Therapeutics plc
  • Alara Pharmaceutical Corporation
  • Antares Pharma, Inc.
  • Apitope Technology (Bristol) Ltd.
  • IONIS Pharmaceuticals, Inc.
  • Immunovant, Inc.
  • HanAll Biopharma Co., Ltd.
  • Cara Therapeutics

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Graves' Disease (Overactive Thyroid) Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Graves' Disease (Overactive Thyroid) Market, By Treatment, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Anti-thyroid Drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Beta Blockers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Iodine Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Radioactive Iodine Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Graves' Disease (Overactive Thyroid) Market, By Route of Administration, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Graves' Disease (Overactive Thyroid) Market, By Distribution Channel, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Graves' Disease (Overactive Thyroid) Market, By Region, 2019 - 2031, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • RLC LABS, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck KGaA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eisai Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aspen Pharmacare Holdings Limited
  • Sanofi
  • GlaxoSmithKline plc
  • AstraZeneca
  • Horizon Therapeutics plc
  • Alara Pharmaceutical Corporation
  • Antares Pharma, Inc.
  • Apitope Technology (Bristol) Ltd.
  • IONIS Pharmaceuticals, Inc.
  • Immunovant, Inc.
  • HanAll Biopharma Co., Ltd.
  • Cara Therapeutics

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact